Skip to content
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
AXON$422.00+7.40(+1.78%)Axon Announces Body 5: Next-Generation Camera Built for the AI Era Axon (Nasdaq: AXON), the global leader in public safety technology, today announced Axon Body 5, its newest body-worn camera designed to bring more...[1:00:00 PM ET]PFE$30.02-0.40(-1.31%)Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026[11:18:00 AM ET]BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]ONC$377.63-4.64(-1.21%)BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026[4:15:00 AM ET]CMPX$0.77-0.03(-3.97%)Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026[4:15:00 AM ET]CELC$63.20-2.37(-3.61%)Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026[4:15:00 AM ET]

CHMG · NASDAQ

Chemung Financial Corporation

$83.86 +0.74 (+0.89%)

Company overview

Chemung Financial Corporation operates as the holding company for Chemung Canal Trust Company that provides a range of banking, financing, fiduciary, and other financial services. The company provides demand, savings, and time deposits; non-interest and interest-bearing checking accounts; and insured money market accounts. It also offers commercial and agricultural loans comprising loans to small and mid-sized businesses; commercial mortgage loans; residential mortgage loans; consumer loans, including home equity lines of credit and home equity term loans; and interest rate swaps, letters of credit, wealth management, employee benefit plans, mutual fund, insurance products, and brokerage services. Further, it provides securities, insurance, and tax preparation services.

Sector
Financial Services
Industry
Banks - Regional
Exchange
NASDAQ
Market cap
$404M
Employees
343
Headquarters
Elmira, NY
CEO
Anders Tomson
Listed
January 4, 1999
P/E
22.19
Dividend yield
1.67%

Company financials

Revenue
$143M
Gross profit
$94.8M
Operating income
$24.1M
EBITDA
$26.1M
Net income
$18.3M
EPS
$3.78
Total assets
$2.7B
Total debt
$129M
Gross margin
66.50%
Net margin
12.83%
Earnings yield
4.51%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

63.4669.3175.1681.0286.87
CHMG 1D NASDAQ O83.75H85.49L83.10C83.88+0.65 (+0.78%)Vol77.21K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Source
Date
Type
Ticker Type Headline Source Published
CHMG Stock news Chemung Financial: Strong Q3 2026 Results But Watch Out For Balance Sheet Constraints Seeking Alpha
CHMG Stock news Compared to Estimates, Chemung Financial (CHMG) Q3 Earnings: A Look at Key Metrics Zacks Investment Research
CHMG Stock news Chemung Financial (CHMG) Tops Q3 Earnings and Revenue Estimates Zacks Investment Research
CHMG Press release Chemung Financial Corporation Reports Third Quarter 2026 Net Income of $12.7 million, or $2.63 per share GlobeNewswire
CHMG Stock news Chemung Financial (CHMG) Earnings Expected to Grow: Should You Buy? Zacks Investment Research
CHMG Press release Chemung Canal Trust Company Announces Plan to Unify Under New Name GlobeNewswire
CHMG Stock news 3 Bank Stocks With Recent Dividend Increases Worth Considering Zacks Investment Research
CHMG Press release Chemung Financial Corporation Announces Dividend Increase GlobeNewsWire
CHMG Stock news All You Need to Know About Chemung Financial (CHMG) Rating Upgrade to Strong Buy Zacks Investment Research
CHMG Stock news Chemung Financial: Completely Flying Under The Radar, But Attractive Seeking Alpha
CHMG Stock news Chemung Financial Corporation: Turnaround Confirmed Seeking Alpha
CHMG Stock news Chemung Financial (CHMG) Q2 Earnings and Revenues Top Estimates Zacks Investment Research
CHMG Press release Chemung Financial Corporation Reports Second Quarter 2026 Net Income of $8.8 million, or $1.82 per share GlobeNewsWire
CHMG Stock news Chemung Financial Corporation (CHMG) Shareholder/Analyst Call Prepared Remarks Transcript Seeking Alpha
CHMG Press release Chemung Financial Corporation Announces Quarterly Dividend GlobeNewsWire
CHMG Stock news Chemung Financial (CHMG) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks Investment Research
CHMG Stock news Why Chemung Financial (CHMG) is a Great Dividend Stock Right Now Zacks Investment Research
CHMG Stock news Why Chemung Financial (CHMG) is a Top Dividend Stock for Your Portfolio Zacks Investment Research
CHMG Stock news Don't Overlook These Top Bank Stocks After Crushing Q1 EPS Expectations: BSVN, CHMG Zacks Investment Research
CHMG Stock news Chemung Financial (CHMG) Beats Q1 Earnings Estimates Zacks Investment Research
FAQ

Questions about Chemung Financial Corporation

What does Chemung Financial Corporation do?
Chemung Financial Corporation operates as the holding company for Chemung Canal Trust Company that provides a range of banking, financing, fiduciary, and other financial services. The company provides demand, savings, and time deposits; non-interest and interest-bearing checking accounts; and insured money market accounts. It also offers commercial and agricultural loans comprising loans to small and mid-sized businesses; commercial mortgage loans; residential mortgage loans; consumer loans, including home equity lines of credit and home equity term loans; and interest rate swaps, letters of credit, wealth management, employee benefit plans, mutual fund, insurance products, and brokerage services. Further, it provides securities, insurance, and tax preparation services.
What is CHMG's market cap?
Chemung Financial Corporation (CHMG) is a listed stock with a live quote. The latest market cap on this page is $404M.
Where is Chemung Financial Corporation headquartered?
Chemung Financial Corporation is headquartered in Elmira, NY.
How do I get CHMG news from the API?
Call GET /v1/news?tickers=CHMG. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does CHMG news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CHMG, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the CHMG price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.